JAGUAR HEALTH, INC. Loss Contingency, Damages Awarded, Value
JAGUAR HEALTH, INC. (JAGX) reported Loss Contingency, Damages Awarded, Value of $2.60 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-31.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LossContingencyDamagesAwardedValue · last filed 2022-11-14
- JAGUAR HEALTH, INC. loss contingency, damages awarded, value for the quarter ending 2020-09-30 was $2.60M.
- JAGUAR HEALTH, INC. loss contingency, damages awarded, value for fiscal 2020 was $2.60M.
| Period end | Loss Contingency, Damages Awarded, Value | Loss Contingency, Damages Awarded, Value 3 month | Loss Contingency, Damages Awarded, Value 12 month |
|---|---|---|---|
| 2020-12-31 | $2.60M 10-K · filed 2021-03-31 | ||
| 2020-09-30 | $2.60M 10-Q · filed 2020-11-16 | ||
| 2019-08-02 | $2.60M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |